Mylan Sold Its Soul – Will Your Sales Team?
OpenSymmetry
NOVEMBER 3, 2016
Just last year, in 2015, CEO Martin Shkreli of Turing Pharmaceuticals was under fire for buying the drug Daraprim from Impax Laboratories and raising the price from $13.50 For starters, niche drugs like EpiPen have virtually no competitors because of the way they cornered the market. So what next – what are the implications?
Let's personalize your content